InvestorsHub Logo
Followers 65
Posts 3561
Boards Moderated 0
Alias Born 07/29/2017

Re: Potomac post# 29492

Tuesday, 10/02/2018 2:27:09 PM

Tuesday, October 02, 2018 2:27:09 PM

Post# of 75976
Yes we discussed at length all weekend. It was very intriguing to see that comment on LinkedIn. Could it be that Merck or one of it's subsidiaries such as Millipore-Sigma is working with UNIVEC/AGRIMED? They have the patch technology but are missing pharmacy grade CBD oil. Dr Dalton has called this very recently a "once in a lifetime opportunity". He even mentioned that the opportunity is bigger than he initially thought.

There is plenty of talk about companies like Merck, Novartis and Pfizer looking to grab small medical cannabis companies as they are currently behind in the race. In fact they must now watch out for "mid-major" pharma like GW that has a head start in the cannabis sector.

So Merck is a possibility. JV? buyout? Who knows? Could also explain why Dr Dalton said he can't talk about the plan due to "legal reasons". Sounds like an NDA is possibly in place. If it was just an in house project he would be able to tell shareholders all about it. If we are working with big Pharma an NDA would certainly explain those legal restrictions imho.

#PRESCRIPTIONCANNABIS